Nexten Bio Acquires 50% Stake in US Rossbivo Therapeutics... "Securing miRNA-Based Pipeline"

[Asia Economy Reporter Hyunseok Yoo] Nexton Bioscience's subsidiary Nexton Bio announced on the 31st that it has acquired a 50% stake in RosVivo Therapeutics, Inc. (hereinafter Rosvivo), based in the United States, for approximately 5.5 million USD.

Accordingly, Nexton Bio has secured pipelines for diabetes treatments based on miRNA, as well as treatments for COVID-19, obesity, non-alcoholic fatty liver disease, and functional gastrointestinal disorders, enabling it to fully strengthen its capabilities as a bio company.

Regarding the investment background, since this is the company's first official move after entering the bio business, due diligence and valuation were conducted on Rosvivo's miRNA technology in collaboration with leading domestic and international law firms, strategic consulting firms, patent firms, and accounting firms. The company explained that it carefully decided on the investment after consulting multiple diabetes specialists about the efficacy of the new drug.

Global major pharmaceutical companies such as Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi have long participated in the development of diabetes treatments and dominate the diabetes market, but existing treatments differ in mechanism from RosVivo’s therapy, which aims for a cure. Side effects and frequent dosing remain burdensome realities for diabetes patients.

RosVivo’s miRNA new drug RSVI-301 significantly reduces the frequency of injections to once every six months and alleviates side effects such as nausea, diarrhea, and digestive disorders, thereby compensating for the weaknesses of existing diabetes drugs. It is expected to establish itself as a next-generation diabetes drug for long-term patients rather than a simple substitute for existing diabetes medications.

Since diabetes treatment currently relies on palliative methods that alleviate symptoms, there is an urgent need to develop curative treatments that address the root causes of diabetes. A Nexton Bio official stated, “Beyond investment, we will collaborate in research and development with RosVivo with a sense of responsibility to conquer diabetes,” adding, “We will do our best to prove the potential of this curative treatment, as presented in miRNA research papers, through upcoming clinical trials so that it can be used as a new treatment option for diabetes patients.”

This content was produced with the assistance of AI translation services.